Fibrosis-Inflammation Lab

⌘K

Fibrosis-Inflammation Lab

Accelerating fibrosis and inflammation research through validated preclinical models and expert insights.

Research

Models
Drugs
Insights
Resources
Pathways

Company

About
Contact Us
Privacy Policy

© 2026 Fibrosis-Inflammation Lab. All rights reserved.

/

/

Pamrevlumab (pamrevlumab) | Accelerate Your Fibrosis Research

Home/Drugs/Pamrevlumab

Pamrevlumab

pamrevlumab

Phase 3

Sponsor: FibroGen

Indication: IPF / Pancreatic Cancer

Mechanism of Action

Connective Tissue Growth Factor (CTGF) inhibitor

Target: CTGF

Clinical Information

Approval Year

Clinical Trials (ClinicalTrials.gov)

TERMINATEDNCT02606136

Trial of Pamrevlumab (FG-3019), in Non-Ambulatory Participants With Duchenne Muscular Dystrophy (DMD)

Phase:PHASE2Org:Kyntra Bio

TERMINATEDNCT00913393

Study of FibroGen (FG)-3019 in Subjects With Type 2 Diabetes Mellitus and Kidney Disease on ACEi and/or ARB Therapy

Phase:PHASE2Org:Kyntra Bio

COMPLETEDNCT00074698

Safety and Tolerability Study of FG-3019 in Participants With Idiopathic Pulmonary Fibrosis

Phase:PHASE1Org:Kyntra Bio

TERMINATEDNCT03955146

Zephyrus I: Evaluation of Efficacy and Safety of Pamrevlumab in Participants With Idiopathic Pulmonary Fibrosis (IPF)

Phase:PHASE3Org:Kyntra Bio

WITHDRAWNNCT02851381

Compassionate Single Subject Use of FG-3019 (FibroGen) in Locally Advanced, Unresectable Pancreatic Cancer

Phase:NAOrg:Jonsson Comprehensive Cancer Center

View all trials on ClinicalTrials.gov

Relevant Publications (PubMed)

Network meta-analysis of pharmacological treatments for idiopathic pulmonary fibrosis: evaluating effects on lung function.

Yin Y, Wu X, Liu Z et al.

Front Pharmacol2026

Caregiver burden in Duchenne muscular dystrophy in Europe, Japan, and the United States - a real-world study.

Strober J, Ishigaki K, Posner N et al.

BMC Neurol2026 Jan 10

Breaking new ground in heart failure management: novel therapies and future frontiers.

Khalid A, Rodriguez P, Tasouli-Drakou V et al.

Front Cardiovasc Med2025

New Challenging Systemic Therapies for Juvenile Scleroderma: A Comprehensive Review.

Sassetti C, Borrelli C, Mazuy M et al.

Pharmaceuticals (Basel)2025 Apr 28

Minimum clinically important difference in Quantitative Lung Fibrosis score associated with all-cause mortality in idiopathic pulmonary fibrosis: subanalysis from two phase II trials of pamrevlumab.

Kim GH, Zhang X, Brown MS et al.

BMJ Open2025 May 12

View more on PubMed

Validated Models

This drug has been validated in the following preclinical models: